MOTS–C 10mg

Mitochondria, often referred to as the “powerhouses of the cell,” are essential organelles that generate energy by breaking down nutrients into usable fuel for cellular functions. Beyond energy production, mitochondria communicate through signaling molecules, enhancing intercellular coordination. Among these molecules is MOTS-c, a mitochondrial-derived peptide (MDP) that plays a vital role in various metabolic functions, including glucose metabolism, muscle synthesis, and maintaining metabolic balance.

How MOTS-c Functions

MOTS-c demonstrates significant therapeutic potential due to its ability to positively influence numerous bodily processes. Key mechanisms include:

• AMPK Activation: Enhancing muscle metabolism and function during metabolic stress.
• Gene Regulation: Modulating genes related to blood sugar restriction and antioxidant defense.
• Collagen Synthesis: Supporting bone health by stimulating type I collagen production in osteoblasts.

Research Highlights on MOTS-c

A. Obesity Treatment

Obesity is a global health challenge linked to heart disease, diabetes, and other conditions. Studies indicate MOTS-c can aid weight management:

• Reduces oxidative stress during exercise, enhancing adaptation and endurance.
• Higher plasma MOTS-c levels are associated with lean individuals.
• In animal studies, MOTS-c reduced fat accumulation and inhibited fat cell formation.
• Prevented diet-induced and age-related obesity and insulin resistance in rodents.

B. Blood Sugar Regulation and Diabetes Management

MOTS-c improves insulin sensitivity and glucose uptake, addressing key issues in diabetes:

• Enhances the body’s response to insulin, lowering blood sugar levels.
• Prevented insulin-producing cell destruction in diabetic mice.
• Protected against muscle wasting and insulin resistance in obesity models.

C. Heart Health

MOTS-c supports cardiovascular health by mitigating inflammation and oxidative stress:

• Correlated with improved coronary function in humans.
• Reduced heart valve calcification and preserved cardiac function in animal studies.

D. Bone Health

Age-related bone loss leads to osteoporosis. MOTS-c counters this by:

• Inhibiting bone breakdown and promoting bone formation in animal models.
• Boosting type I collagen synthesis to strengthen bone structure.

E. Longevity

MOTS-c has been linked to extended life expectancy by maintaining cellular and metabolic homeostasis:

• Associated with increased lifespan in studies of mitochondrial DNA variants.
• Promotes NAD+ production, a molecule critical for aging and cellular repair.

F. Exercise Tolerance

MOTS-c benefits athletes by improving performance and recovery:

• Reduces exercise-induced oxidative stress, enhancing endurance.
• Activates AMPK and increases energy production.

G. Bacterial Infection Defense

MOTS-c shows promise in treating antibiotic-resistant infections such as MRSA by:

• Improving survival rates and reducing bacterial loads in infected animal models.
• Suppressing inflammation during sepsis.

MOTS-c and Cancer

MOTS-c may help counteract the metabolic reprogramming of cancer cells by restoring mitochondrial function and disrupting tumor energy pathways. Its anti-inflammatory and oxidative stress-reducing properties create a less favorable environment for cancer development and progression. Furthermore, MOTS-c’s role in regulating glucose and insulin levels addresses metabolic conditions that can increase cancer risk.

MOTS-c Administration and Side Effects

Injections

MOTS-c injections deliver the peptide directly into the bloodstream, optimizing absorption. This method is effective for:

• Enhancing metabolic efficiency and energy utilization.
• Reducing inflammation and oxidative stress.
• Supporting age-related decline in mitochondrial function.

Side Effects

Reported side effects are rare and may include:

• Lipid profile alterations.
• Fluid retention.
• Development of antibodies.
• Stomach discomfort or changes in blood sugar levels.

References

1. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free RadicBiol Med. 2016;100:182–187. doi:10.1016/j.freeradbiomed.2016.05.015.
2. Yun J, Finkel T. Mitohormesis. Cell Metab. 2014;19(5):757–766.
3. Thevis M, Schanzer W. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs. Rapid Commun Mass Spectrom. 2016;30(5):635–651.
4. Merry TL, Ristow M. Mitohormesis in exercise training. Free RadicBiol Med. 2015
5. Handschin C. Caloric restriction and exercise “mimetics”: ready for prime time? Pharmacol Res. 2015;103:158–166.
6. Hunter P. Exercise in a bottle: elucidating how exercise conveys health benefits might lead to new therapeutic options for a range of diseases from cancer to metabolic syndrome. EMBO Rep. 2016.
7. Li S, Laher I. Exercise pills: at the starting line. Trends PharmacolSci. 2015.
8. Lee DE, et al. Translational machinery of mitochondrial mRNA is promoted by physical activity in Western diet-induced obese mice. Acta Physiol. 2016.
9. Cataldo LR, Fernández-verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med. 2018;66(6):1019-1022.
10. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
11. Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med. 2019;97(4):473-485.
12. Lee C, Zeng J, Drew BG, Sallam T, Martin‐Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (2015) The mitochondrial‐derived peptide MOTS‐c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 21, 443–454.
13. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free RadicBiol Med. 2016;100:182–187. doi:10.1016/j.freeradbiomed.2016.05.015.
14. Zempo, H., Kim, S. J., Fuku, N., Nishida, Y., Higaki, Y., Wan, J., Yen, K., Miller, B., Vicinanza, R., Miyamoto-Mikami, E., Kumagai, H., Naito, H., Xiao, J., Mehta, H. H., Lee, C., Hara, M., Patel, Y. M., Setiawan, V. W., Moore, T. M., Hevener, A. L., … Cohen, P. (2021). A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging, 13(2), 1692–1717.https://doi.org/10.18632/aging.202529.
15. Kim SJ, Miller B, Kumagai H, Yen K, Cohen P. MOTS-c: an equal opportunity insulin sensitizer. J Mol Med. 2019;97(4):487-490.
16. Kong, B. S., Min, S. H., Lee, C., & Cho, Y. M. (2021). Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell reports, 36(4), 109447. https://doi.org/10.1016/j.celrep.2021.109447.
17. Kumagai, H., Coelho, A. R., Wan, J., Mehta, H. H., Yen, K., Huang, A., Zempo, H., Fuku, N., Maeda, S., Oliveira, P. J., Cohen, P., & Kim, S. J. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. American journal of physiology. Endocrinology and metabolism, 320(4), E680–E690.https://doi.org/10.1152/ajpendo.00275.2020.
18. Qin Q, Delrio S, Wan J, et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. International journal of cardiology. 2018; 254:23-27.
19. Li H, Ren K, Jiang T, Zhao GJ. MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-κB pathway. Int J Cardiol. 2018;268:40.
20. Yuan, J., Wang, M., Pan, Y., Liang, M., Fu, Y., Duan, Y., Tang, M., Laher, I., & Li, S. (2021). The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats. Scientific reports, 11(1), 20077.https://doi.org/10.1038/s41598-021-99568-3.
21. Wei, M., Gan, L., Liu, Z., Liu, L., Chang, J. R., Yin, D. C., Cao, H. L., Su, X. L., & Smith, W. W. (2020). Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. Cardiorenal medicine, 10(1), 42–50.https://doi.org/10.1159/000503224.